Storage Stability
Trefoil factor 2 (TFF2), historically called spasmolytic polypeptide, is a 10.6 kDa peptide carrying two trefoil domains (making it unique among trefoil factors). It is produced exclusively by mucous neck cells of the gastric body and Brunner glands of the duodenum. TFF2 is the key mediator of the spasmolytic polypeptide-expressing metaplasia (SPEM), an important gastric pre-cancerous lesion and a pathway to intestinal-type gastric cancer.
Mechanism of Action
- Dual trefoil domain structure creates a larger, more stable molecular architecture than TFF1/TFF3; enables stronger mucin gel bridging
- Promotes gastric epithelial cell restitution after superficial injury via FAK and PI3K/Akt activation
- Inhibits gastric smooth muscle contraction (the original spasmolytic property); acts on vagally-mediated contractile circuits
- TFF2 upregulation in response to H. pylori infection and parietal cell injury drives SPEM: reprogramming of chief cells to mucous metaplasia expressing TFF2+
- SPEM is a risk lesion for gastric cancer; TFF2 expression marks this pre-neoplastic state; loss of TFF2 in established cancer correlates with poor prognosis
Research Findings
- TFF2 knockout mice develop more severe gastric damage after challenge with indomethacin or HCl, confirming gastric mucosal protective function
- TFF2 overexpression in transgenic mice drives SPEM formation and increases susceptibility to carcinogen-induced gastric cancer, showing it is both protective (short-term) and pro-oncogenic (chronically)
- Recombinant TFF2 accelerated healing of gastric ulcers in rodents when given intragastrically (5-50 mg/kg twice daily)
- H. pylori infection elevates TFF2 mRNA and protein in gastric body; SPEM TFF2 immunostaining is used pathologically to identify metaplastic mucosa
- TFF2 suppresses migration and invasion in some cancer cell lines while promoting invasion in others, reflecting complex context-dependent roles
Research Protocols
- Gastric ulcer healing: 1-50 mg/kg IG or IV recombinant TFF2 in aspirin-induced or acetic acid ulcer models in rodents
- SPEM induction model: TFF2 transgenic mice or IP injection of DMP-777 (parietal cell toxin); TFF2 IHC to confirm metaplasia
- Smooth muscle spasmolysis: 100 nM-10 mcM TFF2 on precontracted gastric smooth muscle strip; measure tension reduction
- Mucin interaction: TFF2 co-immunoprecipitation with MUC5AC from gastric mucus by Western blot analysis
Interactions
- TFF1 and TFF3: family members; TFF2 contains two trefoil domains vs one; TFF2 is uniquely expressed in gastric mucous neck cells and Brunner glands
- MUC5AC and MUC6 mucins: TFF2 physically binds and stabilizes mucin polymers in gastric mucus gel
- H. pylori CagA: bacterial virulence factor that drives TFF2 upregulation and SPEM induction in infected gastric corpus
Safety Profile
Endogenous gastric protective peptide. Recombinant TFF2 well tolerated in animal ulcer studies. No clinical therapeutic approval. Chronic TFF2 elevation (as in SPEM) associated with increased cancer risk; therapeutic window is short-term acute use for mucosal repair.
Legal & Regulatory
Research/investigational; no approved therapeutic product
Ready to dose TFF2 (Spasmolytic Polypeptide)?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
More in Tissue Repair
View all →